Marc Subirats is a general partner at Nina Capital and, per the firm's team page, also sits on the board of Nina Capital SGEIC, S.A. His biography on the firm's site says he is a native of Barcelona, the son of a Swiss mother and a Catalan father, that he studied Economics in Barcelona and in the Netherlands and then pursued an MBA at IESE Business School, and that an entrepreneurship class led him to co-found Advance Medical, which he led for twenty years, building operations in more than ten countries before the company was acquired by US-based TELADOC. He joined Nina Capital after meeting Marta G. Zanchi. He has been quoted in the firm's own fund announcements since 2021, as "partner" in July 2021 and as "General Partner" from February 2022 onwards. IO Health's October 2025 seed round announcement states that he was being added to that company's board of directors.
Education
MBA, IESE Business School
Previous Experience
Advance Medical - co-founder, and led the company for twenty years before its acquisition by US-based TELADOC
Notable Investments
IO Health
Career Timeline
2021
Quoted as "partner" at Nina Capital in the firm's 28 July 2021 announcement of the launch of its second fund.
2022
Quoted as "General Partner" at Nina Capital in the firm's 16 February 2022 announcement of the oversubscribed close of Fund II.
2025
Named in IO Health's 15 October 2025 seed round announcement as being added to the IO Health Board of Directors: "The founding team's deep operational expertise is soon to be expanded even further with the addition of Marc Subirats, General Partner of Nina Capital, to the IO Health Board of Directors." The wording is prospective, so the seat is not recorded in boardSeats.
2025
Quoted as "General Partner" in the February 2025 coverage of the first close of Nina Capital's EUR 50 million Fund III.